real peptides FAQ

Add a growth hormone secretagogue and reduce your caloric deficit slightly. The plateau likely reflects adaptive thermogenesis (reduced metabolic rate) and increased muscle protein breakdown. Both of which GLP-1 agonists don't address. CJC-1295/Ipamorelin or MK-677 maintains anabolic signaling and prevents the metabolic slowdown that occurs when the body starts sacrificing muscle. Research from the Journal of Clinical Endocrinology & Metabolism found that subjects using GH secretagogues during prolonged deficits maintained 92% of lean mass versus 78% in placebo, which translates to 60–100 additional calories burned per day from preserved muscle tissue.

Growth hormone secretagogues take 14–21 days to produce measurable IGF-1 elevation and metabolic rate changes. The lag reflects the time required for hepatic IGF-1 synthesis and downstream anabolic signaling to establish. If no change occurs by week three, the most common causes are underdosing (effective MK 677 doses start at 12.5mg daily), dosing at inconsistent times (which disrupts pulsatility), or administering peptides that have degraded due to improper storage. Verify refrigeration at 2–8°C for reconstituted peptides and confirm dosing consistency before concluding non-response.

Stacking MK 677 with Thymalin or Cartalax is mechanistically sound because they target different pathways. GH secretagogue action doesn't overlap with thymic immune modulation or mitochondrial signaling. Stacking two GHS compounds (e.g., MK 677 + GHRP-2) provides no additive benefit and increases the risk of receptor desensitization. Combining GLP-1 agonists with GHS is common in metabolic research but requires monitoring for glucose dysregulation since GH opposes insulin action while GLP-1 enhances it.

GH-induced water retention occurs because growth hormone increases sodium reabsorption in the kidneys and stimulates aldosterone secretion. This is a normal physiological response, not a sign of impurity or poor-quality peptide. The retention typically resolves within 4–6 weeks as the body adjusts to elevated GH levels. Reducing sodium intake to under 2,000mg daily and ensuring adequate hydration (3–4 liters) accelerates adaptation. Persistent edema beyond eight weeks may indicate dosing above physiological range. Consider reducing dose by 25% and reassessing.

Structure dosing around known craving trigger windows rather than attempting 24-hour coverage. Hexarelin's 30–45 minute half-life means it functions as an acute intervention, not a baseline suppression tool. Research protocols using hexarelin for appetite studies dose 30–60 minutes before scheduled meals or identified craving periods (mid-afternoon, post-dinner). This is practical only if your cravings follow a predictable pattern. For spontaneous or all-day cravings, a longer-acting GLP-1 agonist is more appropriate.

This is expected. The mechanism (appetite suppression) becomes less relevant as ghrelin stays elevated regardless of peptide use and adaptive thermogenesis dominates. Switch to a metabolic modulator like tesofensine or add survodutide if available. Tesofensine increases resting metabolic rate independent of appetite, which directly counteracts the thyroid downregulation and NEAT reduction that occur below 15% body fat. Alternatively, take a 10–14 day diet break at maintenance calories to reset leptin signaling and metabolic rate, then resume the deficit with a different peptide stack.

Increase dose under prescriber guidance or assess timing of carbohydrate intake relative to injection day. Semaglutide's gastric emptying effect peaks 48–72 hours post-injection and tapers toward the end of the weekly cycle. Patients who inject Friday and experience breakthrough cravings Thursday are under-dosed or metabolizing the peptide faster than average. The STEP-1 protocol titrated to 2.4mg over 20 weeks specifically to avoid this trough effect. If you're at maintenance dose and cravings persist, examine macronutrient timing: high-carb meals early in the weekly cycle may still trigger insulin spikes that overwhelm GLP-1's glucose-buffering capacity.

MC4R agonists restore leptin sensitivity and reduce hedonic eating, but access is restricted to genetic obesity diagnoses. If you've been in prolonged caloric deficit (12+ months) or have documented leptin resistance (serum leptin >30 ng/mL with BMI >30), you may benefit from peptides that act downstream of leptin signaling rather than depending on intact leptin pathways. Tirzepatide's GIP component enhances insulin sensitivity independent of leptin, which is why some leptin-resistant individuals respond better to dual agonists than GLP-1-only compounds. This requires metabolic testing and prescriber evaluation. Not self-diagnosis.

Use a growth hormone secretagogue as the primary peptide and control the deficit through diet alone. GLP-1 agonists will cause muscle loss if protein intake and training stimulus aren't sufficient. The appetite suppression works so effectively that many users under-eat protein without realising it. A 180-pound male at 12% body fat needs 180–200g protein daily to maintain nitrogen balance in a deficit. Stack CJC-1295/Ipamorelin with high-frequency resistance training (4–5 sessions per week) and keep the caloric deficit modest (300–400 calories below maintenance). Expect 0.5–0.7 pounds of fat loss per week. Slower than GLP-1 protocols but with near-zero muscle loss.

Glutathione will reduce baseline oxidative stress and protect existing cellular structures—but without new collagen synthesis (GHK-Cu) or the energy to produce it (NAD+), you're simply slowing degradation rather than enabling regeneration. This is maintenance, not remodeling. Oxidative defense is essential, but it's downstream of biosynthesis: if no new collagen is being produced, there's nothing to protect. Glutathione also cannot reverse oxidative damage that has already occurred—it prevents future damage, but doesn't repair carbonylated proteins or oxidized lipids already present in aged dermis.

Administer the missed dose as soon as you recognize the lapse, provided it falls within 48 hours of the scheduled time, then resume the regular dosing schedule. If more than 48 hours have passed, skip the missed dose entirely and continue with the next planned administration. Do not double-dose to compensate. Glutathione plasma levels return to baseline within 24–36 hours after subcutaneous injection, but tissue stores (particularly in liver and erythrocytes) remain elevated for 3–5 days. A single missed dose in a chronic supplementation protocol is unlikely to disrupt research endpoints meaningfully, but repeated inconsistency introduces variability that compromises data quality. Document all protocol deviations in research logs.

Cease injections at that site immediately and rotate to a new location. Persistent inflammation indicates either localized immune response or bacterial contamination. GHK-Cu can cause mild blue-green discoloration that resolves in 48–72 hours, but redness lasting beyond 96 hours suggests contamination or improper reconstitution technique. Epithalon and bioregulators should produce minimal injection site reaction; swelling beyond 24 hours is abnormal. If multiple injection sites show persistent inflammation, the reconstituted solution is likely contaminated. Discard the vial and reconstitute fresh product using aseptic technique. Never inject air into vials, always swab injection sites with alcohol before needle insertion, and refrigerate immediately after each use.

Use a medical-grade cooler designed for peptide transport, maintaining internal temperature between 2–8°C. Insulin coolers like FRIO wallets use evaporative cooling to maintain this range for 36–48 hours without ice or electricity, making them suitable for short-term transport. Avoid placing vials in direct contact with ice packs, as freezing causes irreversible protein aggregation; instead, use gel packs wrapped in cloth to create a buffer zone. Monitor temperature with a digital thermometer throughout transport. If refrigeration cannot be maintained for longer than 6–8 hours, plan to use the dose immediately upon arrival rather than returning it to storage. Temperature cycling degrades peptide integrity faster than sustained ambient exposure.

Discard the vial immediately. Cloudiness indicates bacterial contamination or peptide aggregation, both of which compromise study validity. Copper peptides should produce a clear, pale blue solution when reconstituted correctly; any turbidity, particulate matter, or color shift toward green or brown signals degradation. Common causes include reconstitution with non-sterile water, storage above 8°C, or UV exposure during handling. To prevent recurrence, always use fresh bacteriostatic water stored at 2–8°C, inject slowly to avoid foaming (which denatures peptides), and store reconstituted vials in light-blocking containers. If contamination occurs across multiple vials from the same batch, contact Real Peptides for replacement. Batch-level quality issues are rare but warrant immediate supplier notification.

Design a three-arm randomized controlled trial: Glow Stack monotherapy, retinoid monotherapy (tretinoin 0.05% or adapalene 0.1%), and combination therapy (Glow Stack + retinoid). This design isolates the effect of each intervention while testing whether peptides provide additive benefit beyond retinoid alone. A clinically meaningful question given that retinoids remain the gold standard for photoaging but produce irritation in 30–40% of subjects during initial titration. Copper peptides have demonstrated anti-inflammatory properties in wound healing models, suggesting they may mitigate retinoid-induced erythema and peeling when combined. The primary endpoint should be composite radiance scoring (combining melanin homogeneity, dermal thickness, and fine-line depth) measured at 12 and 24 weeks, with secondary endpoints tracking tolerability and adverse event rates.

Mild erythema or induration at the injection site resolves spontaneously within 24–48 hours and typically indicates subcutaneous depot formation rather than an adverse reaction. Persistent pain, swelling, or warmth suggests either improper injection technique (administration into muscle rather than subcutaneous fat) or pH-related tissue irritation from the solution. Glutathione solutions with pH below 3.0 or above 7.0 can cause localized discomfort; verify pH with indicator strips if reactions persist. Rotate injection sites systematically. Abdomen, lateral thigh, upper arm. To prevent localized inflammation from repeated trauma. If reactions continue despite site rotation and verified reconstitution technique, reduce the dose to 200mg and assess tolerance before escalating.

GHK-Cu will upregulate COL1A1 and COL3A1 gene transcription, increasing procollagen mRNA levels—but if mitochondrial ATP production is insufficient (low NAD+), ribosomes cannot sustain translation and mRNA degrades before protein synthesis completes. Even if some collagen is synthesized, oxidative stress (without glutathione) will damage those proteins during post-translational hydroxylation, when prolyl hydroxylase enzymes generate hydrogen peroxide as a byproduct. The result: elevated gene expression with minimal functional collagen deposition. We've reviewed this pattern across dermal research protocols—transcriptional activation without energetic and antioxidant support produces negligible structural change.

Increased ATP availability will improve general cellular function, including immune activity, DNA repair, and possibly fibroblast proliferation—but without a transcriptional signal to produce collagen (GHK-Cu), that ATP is allocated to whichever metabolic process is most energy-starved at the time. In aged skin, chronic low-grade inflammation (inflammaging) is often the dominant energy sink, meaning NAD+ alone may reduce inflammatory markers without producing visible dermal remodeling. Collagen synthesis requires not just energy, but also the genetic instruction to produce procollagen mRNA—without GHK-Cu binding integrin receptors, that instruction never arrives.

Discard it immediately. Do not inject. Peptide solutions stored above 8°C for more than 4–6 hours undergo irreversible structural changes that render them inactive or potentially immunogenic. GHK-Cu copper binding destabilizes at ambient temperature, causing copper ion dissociation that produces inactive glycyl-histidyl-lysine fragments. Epithalon's tetrapeptide structure is particularly vulnerable to thermal degradation. Studies in Protein and Peptide Letters show 40–60% activity loss after 12 hours at 20–25°C. The solution may still appear clear, but bioactivity is compromised. Proper storage requires refrigeration at 2–8°C immediately after reconstitution, with temperature logging if conducting formal research protocols.

Reconstitute Glow Stack at higher concentration (0.5mL bacteriostatic water per 5mg peptide) to create a topical serum, then incorporate into a liposomal carrier or penetration-enhancing base. Topical peptide delivery faces bioavailability challenges: the stratum corneum blocks molecules larger than 500 Daltons, and GHK-Cu (molecular weight 340 Da) sits near this threshold while copper ion binding increases effective size. Research using topical GHK-Cu typically employs liposomal encapsulation or iontophoresis to improve dermal penetration. One study published in Journal of Cosmetic Dermatology found that liposomal GHK-Cu achieved 23% higher dermal copper levels compared to aqueous formulations. Labs lacking liposomal preparation equipment may partner with compounding facilities specializing in transdermal delivery systems, though this introduces additional variables into study design.